Related Experiment Videos
[Primary pulmonary hypertension: new treatment options]
S Madan1, A Boonstra, R M Berger
1Sophia Kinderziekenhuis/Academisch Ziekenhuis, afd. Kindergeneeskunde, onderafd. Kindercardiologie, Dr. Molewaterplein 60, 3015 GJ Rotterdam.
Nederlands Tijdschrift Voor Geneeskunde
|October 12, 2001
Summary
Primary pulmonary hypertension (PPH) is a rare, life-threatening vascular disease. Recent treatment advances have improved survival and quality of life for PPH patients.
Area of Science:
- Cardiology
- Pulmonology
- Vascular Biology
Context:
- Primary pulmonary hypertension (PPH) is a rare, progressive, and fatal pulmonary vascular disease.
- It leads to elevated pulmonary vascular resistance, pulmonary hypertension, and right ventricle failure.
- PPH most frequently affects women aged 20-30, with a mean survival of 2-3 years post-symptom onset.
Purpose:
- To review current treatment options for Primary Pulmonary Hypertension (PPH).
- To highlight recent advances in PPH management.
- To discuss the impact of these advances on patient survival and quality of life.
Summary:
- PPH is characterized by high pulmonary vascular resistance and right heart failure.
- Current treatments include anticoagulants, calcium channel blockers, prostacyclin therapy, and transplantation.
- Intravenous epoprostenol, while effective, presents significant patient management challenges.
Impact:
- Major advances in PPH treatment over the last decade have significantly improved patient outcomes.
- Enhanced survival and quality of life are achievable for many PPH patients.
- Effective management requires careful patient selection and robust healthcare infrastructure.